Stock info Sorrento Therapeutics | Filter  Basic-Info

Sorrento Therapeutics

The company mostly operates in the pharmaceutical sector. The past 10 years the (international) industry gained at around 75 percent. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.

Past year was a negative year for Sorrento Therapeutics investors

The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 36 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 37 percent. Sorrento Therapeutics's revenues between 2011 and 2015 were quite unstable and moved between 0,58 million dollars and 4,59 million dollars. During 2011 and 2015 Sorrento Therapeutics's net results were quiet stable and fluctuated between -3,24 million dollars and -50,07 million dollars.

Sorrento Therapeutics didn't pay out any dividends (in the past 5 years).

Sorrento Therapeutics' balance mostly financed with equity

As per the end of 2015 the American company's balance sheet equaled 343,52 million dollars. Last year the total debt of the company was 198,37 million dollars. This equals around 57,75 percent of the total balance sheet. As per the end of 2015 Sorrento Therapeutics's price/earnings-ratio equaled -4. So investors paid for 1 stock -4 times the earnings per share of 2015. Based on the classical stock valuation theories the American stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 300,81 million dollars. At the end of 2015 the American company had around 36,91 million stocks listed.

All Sorrento Therapeutics's financial reports are available here. More information about Sorrento Therapeutics can be found it's website. .